Clinical Research Directory
Browse clinical research sites, groups, and studies.
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Sponsor: Quanta Therapeutics
Summary
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
Official title: A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
237
Start Date
2025-01-14
Completion Date
2029-01-02
Last Updated
2026-03-02
Healthy Volunteers
No
Conditions
Interventions
QTX3544
QTX3544 will be administered at protocol defined dose.
Cetuximab
Cetuximab will be administered at protocol defined dose.
Locations (10)
Sarah Cannon Research Institute
Denver, Colorado, United States
Yale Cancer Center
New Haven, Connecticut, United States
Florida Cancer Specialists & Research Institute
Sarasota, Florida, United States
South Texas Accelerated Research Therapeutics, LLC Midwest
Grand Rapids, Michigan, United States
Duke Cancer Center
Durham, North Carolina, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
South Texas Accelerated Research Therapeutics, LLC San Antonio
San Antonio, Texas, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
South Texas Accelerated Research Therapeutics Mountain Region, LLC
West Valley City, Utah, United States